Finance

Lists
Why is EBS up 3,67%?
Dive Deeper
EBS:NYSE
Emergent Biosolutions Inc
USD 7,06
+3,67%
(+0,25) 1D
USD 7,01
-0,71% (-0,050)
After hours
Closed: 9 Okt., 16:00:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
USD 6,73
High
USD 7,06
Low
USD 6,60
Mkt. cap
361,99 m
Avg. vol.
1,18 m
Volume
850,96 k
52-wk high
USD 14,06
52-wk low
USD 4,36
EPS
-USD 3,51
Beta
2,28
Shares outstanding
51,27 m
No. of employees
900
Open
USD 6,73
High
USD 7,06
Low
USD 6,60
Mkt. cap
361,99 m
Avg. vol.
1,18 m
Volume
850,96 k
52-wk high
USD 14,06
52-wk low
USD 4,36
EPS
-USD 3,51
Beta
2,28
Shares outstanding
51,27 m
No. of employees
900
News stories
From web sources and news partners
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
Founded05 Sep. 1998
HeadquartersRockville, Maryland, Verenigde State van Amerika
Sector-
Websiteemergentbiosolutions.com
Analyst ratings
Based on 2 analysts giving stock ratings to EBS in the past 3 months
Hold
Buy
1
Hold
0
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for EBS in the last 3 months.
Highest
Current USD 7,06
USD 10,00 (+41,64%)
Average
USD 10,00 (+41,64%)
Lowest
USD 10,00 (+41,64%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
USD 10,00
+41,6%
09/09/2026
Jessica Fye
J.P. Morgan
Sell
Initiated
-
-
08/21/2026
Last report
05 Aug. 2026
Fiscal period
Q2 2026
USD 0,60 / USD 0,11
+445,45%beat
Revenue / Est. (USD)
234,30 m / 177,50 m
+32,00%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
231,10 m
148,70 m
156,10 m
234,30 m
Cost of goods sold
99,00 m
94,00 m
82,40 m
106,10 m
Cost of revenue
99,00 m
94,00 m
82,40 m
106,10 m
Research and development expenses
200,00 k
-600,00 k
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28,30 m
61,60 m
46,60 m
44,60 m
Operating expense
44,80 m
77,30 m
63,10 m
61,80 m
Total operating expenses
143,80 m
171,30 m
145,50 m
167,90 m
Operating income
87,30 m
-22,60 m
10,60 m
66,40 m
Other non operating income
-3,70 m
-8,10 m
13,90 m
-
EBT including unusual items
57,60 m
-50,70 m
13,40 m
-166,30 m
EBT excluding unusual items
68,40 m
-45,40 m
13,50 m
56,40 m
Income tax expense
6,40 m
3,90 m
6,60 m
13,90 m
Effective tax rate
11,11%
-7,69%
49,25%
-8,36%
Other operating expenses
-
-
-
-
Net income
51,20 m
-54,60 m
6,80 m
-180,20 m
Net profit margin
22,15%
-36,72%
4,36%
-76,91%
Earnings per share
1,06
-0,43
0,21
0,60
Interest and investment income
-
-
-
-
Interest expense
-15,20 m
-14,70 m
-11,00 m
-10,00 m
Net interest expenses
-15,20 m
-14,70 m
-11,00 m
-10,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
110,30 m
2,40 m
33,50 m
89,90 m
Gain or loss from assets sale
2,20 m
-11,20 m
800,00 k
11,90 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme